title: [Paget's disease of bone: new therapeutic strategies].
abstract: Paget's disease of bone is a chronic disorder of unknown etiology that can result in enlarged and misshapen bones. The excessive breakdown and formation of bone tissue cause affected bones to weaken, resulting in pain, misshapen bones, fractures, and arthritis in the joints. In most cases the diagnosis is achieved casually, as only 5% of patients develop burning pain at the level of affected bones. As regards therapy, the use of anti-reabsorbing drugs, such as bisphosphonates and calcitonin, appears reasonable. Given the disease pathogenesis, the administration of denosumab and tocilizumab may be a valuable alternative to inhibit RANK expression, and thus osteoclast formation, and interleukin-6 production.
authors.forename: Massimo
authors.initials: M
authors.lastname: D'Amore
authors.forename: Sabrina
authors.initials: S
authors.lastname: Lisi
authors.forename: Margherita
authors.initials: M
authors.lastname: Sisto
authors.forename: Anna Valentina
authors.initials: AV
authors.lastname: De Marino
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000175:diagnosis; D002116:Calcitonin / Q000627:therapeutic use; D000069448:Denosumab; D003937:Diagnosis, Differential; D004164:Diphosphonates / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D018740:Genetic Heterogeneity; D020022:Genetic Predisposition to Disease; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology; D010001:Osteitis Deformans / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics / Q000503:physiopathology; D010010:Osteoclasts / Q000473:pathology; D010019:Osteomyelitis / Q000175:diagnosis; D010024:Osteoporosis / Q000175:diagnosis; D018184:Paramyxoviridae Infections / Q000150:complications; D053245:RANK Ligand / Q000502:physiology; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000235:genetics / Q000502:physiology; D000071456:Sequestosome-1 Protein; D000093242:Interleukin-6 Inhibitors
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D002116:Calcitonin; D000069448:Denosumab; D004164:Diphosphonates; D015850:Interleukin-6; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D000071456:Sequestosome-1 Protein; D000093242:Interleukin-6 Inhibitors; C508600:IL6 protein, human; C099718:SQSTM1 protein, human; C505686:TNFRSF11A protein, human; C505688:TNFSF11 protein, human; C502936:tocilizumab